➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Dow
Harvard Business School
Mallinckrodt
Johnson and Johnson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

LIPO-HEPIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Lipo-hepin, and when can generic versions of Lipo-hepin launch?

Lipo-hepin is a drug marketed by 3M and is included in one NDA.

The generic ingredient in LIPO-HEPIN is heparin sodium. There are seventy-seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Lipo-hepin

A generic version of LIPO-HEPIN was approved as heparin sodium by HOSPIRA on April 28th, 1983.

  Start Trial

Summary for LIPO-HEPIN
Drug patent expirations by year for LIPO-HEPIN

US Patents and Regulatory Information for LIPO-HEPIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
3m LIPO-HEPIN heparin sodium INJECTABLE;INJECTION 017027-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
3m LIPO-HEPIN heparin sodium INJECTABLE;INJECTION 017027-009 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
3m LIPO-HEPIN heparin sodium INJECTABLE;INJECTION 017027-008 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Merck
Medtronic
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.